HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Makoto Naoi Selected Research

rasagiline (Azilect)

1/2013''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
4/2012Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
1/2010Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
8/2009Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
5/2004N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.
5/2003Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.
8/2002Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.
6/2002An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Makoto Naoi Research Topics

Disease

18Parkinson Disease (Parkinson's Disease)
06/2013 - 06/2002
10Neurodegenerative Diseases (Neurodegenerative Disease)
03/2013 - 05/2004
8Neuroblastoma
01/2006 - 03/2002
2Mitochondrial Diseases (Mitochondrial Disease)
01/2005 - 01/2002
1Inflammation
01/2010
1Pheochromocytoma
07/2009
1Alzheimer Disease (Alzheimer's Disease)
01/2005
1Lewy Body Disease (Lewy Body Dementia)
05/2003
1Retinitis Pigmentosa (Pigmentary Retinopathy)
01/2002
1Muscle Weakness
01/2002
1Ataxia (Dyssynergia)
01/2002
1Leigh Disease (Leigh's Disease)
01/2002

Drug/Important Bio-Agent (IBA)

11Dopamine (Intropin)FDA LinkGeneric
06/2013 - 03/2002
9Monoamine Oxidase (MAO)IBA
03/2013 - 01/2005
8rasagiline (Azilect)FDA Link
01/2013 - 06/2002
5salsolineIBA
05/2004 - 08/2002
4Selegiline (E250)FDA LinkGeneric
01/2013 - 08/2009
3NeurotoxinsIBA
03/2013 - 01/2006
3Nerve Growth Factors (Neurotrophins)IBA
04/2012 - 08/2009
2Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
01/2013 - 05/2004
2Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA
01/2013 - 01/2010
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2012 - 01/2011
2Neuroprotective AgentsIBA
01/2010 - 05/2004
2neuromelaninIBA
11/2009 - 06/2008
2Proteins (Proteins, Gene)IBA
01/2005 - 11/2003
2OxygenIBA
01/2005 - 11/2003
2NitrogenIBA
01/2005 - 11/2003
11- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
01/2011
1Proteasome Endopeptidase Complex (Proteasome)IBA
01/2010
1sesaminIBA
07/2009
1Biogenic Amines (Biogenic Amine)IBA
01/2005
1Caspase 9IBA
09/2004
1Caspase 3 (Caspase-3)IBA
09/2004
1Caspase 8 (Caspase-8)IBA
09/2004
1Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
09/2004
1LigninIBA
09/2004
1Neurotransmitter Agents (Neurotransmitter)IBA
05/2004
1N-propargylIBA
05/2004
1NF-kappa B (NF-kB)IBA
05/2004
1Messenger RNA (mRNA)IBA
05/2004
1Transcription Factors (Transcription Factor)IBA
05/2004
1salsolinol N-methyltransferaseIBA
01/2004
1RotenoneIBA
11/2003
1Acrolein (Aqualin)IBA
11/2003
1Cholinesterases (Cholinesterase)IBA
05/2003
1salsolinolIBA
09/2002
1Cytochromes c (Cytochrome c)IBA
08/2002
1Oxidopamine (6 Hydroxydopamine)IBA
03/2002
1DNA Restriction Enzymes (Restriction Endonuclease)IBA
01/2002
1EnzymesIBA
01/2002
1Protons (Proton)IBA
01/2002